絞り込み

16640

広告

ダビンチ没後500年記念 最大規模の特別展 仏ルーブル美術館

ルネサンスの巨匠、レオナルド・ダビンチの没後500年を記念して、世界中からダビンチやその弟子たちの作品を集めた過去最大規模の特別展が、24日からフランスのルーブ...

  1. [企業] Provention Bio社...
  2. クルド人はどんな人たち? 4カ国に暮らす...
  3. インフルエンザ新防御機構を東大が解明、効...
  4. ニホンザル 餌を得るため2匹が協力 初め...

ニュース一覧

Conversion of Quinazoline Modulators from Inhibitors to Activators of β-Glucocerebrosidase.

著者 Zheng J , Jeon S , Jiang W , Burbulla LF , Ysselstein D , Oevel K , Krainc D , Silverman RB
J Med Chem.2019 Jan 15 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (67view , 0users)

Full Text Sources

Research Materials

Gaucher's disease is a lysosomal disease caused by mutations in the β-glucocerebrosidase gene ( GBA1 and GCase) that have been also linked to increased risk of Parkinson's disease (PD) and Diffuse Lewy body dementia. Prior studies have suggested that mutant GCase protein undergoes misfolding and degradation, and therefore, stabilization of the mutant protein represents an important therapeutic strategy in synucleinopathies. In this work, we present a structure-activity relationship (SAR) study of quinazoline compounds that serve as inhibitors of GCase. Unexpectedly, we found that N-methylation of these inhibitors transformed them into GCase activators. A systematic SAR study further revealed that replacement of the key oxygen atom in the linker of the quinazoline derivative also contributed to the activity switch. PD patient-derived fibroblasts and dopaminergic midbrain neurons were treated with a selected compound (9q) that partially stabilized GCase and improved its activity. These results highlight a novel strategy for therapeutic development of noninhibitory GCase modulators in PD and related synucleinopathies.
PMID: 30645117 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード